Recent Updates
Recently added Catalysts
HRTX Positive Sentiment Score: 65/100

Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024

Wednesday, February 28, 2024 2 min read
Key Takeaway: Heron Therapeutics, Inc. has scheduled a conference call for March 12, 2024, to report its fourth quarter and full year 2023 financial results. The call will discuss recent business highlights and can be accessed by both U.S. and international participants. The company aims to improve patient care through its innovative drug development pipeline. An archive of the call will be available on their website for 60 days following the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Heron Therapeutics is announcing its financial results, indicating organizational transparency and engagement with investors.
  • The company continues to emphasize its focus on improving patient lives through innovative therapeutic solutions.

Full Press Release Details

SAN DIEGO, Feb. 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, March 12, 2024, at 4:30 p.m. ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights.
The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 6135354 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
SOURCE Heron Therapeutics, Inc.

21 %

more press release views with

Frequently Asked Questions

When is the Heron Therapeutics conference call?

The conference call is scheduled for March 12, 2024, at 4:30 p.m. ET.

How can I access the Heron Therapeutics conference call?

You can join by calling (646) 307-1963 in the U.S. or (800) 715-9871 internationally.

Where can I find the webcast of the conference call?

The webcast will be available under the Investor Relations section of Heron's website.

Will the conference call be available later?

Yes, an archive of the call will be accessible on Heron's website for 60 days.

What does Heron Therapeutics focus on?

Heron Therapeutics aims to improve patient lives through therapeutic innovations in healthcare.

Tags: HRTX Viatris Investor Conferences Healthcare Heron Therapeutics financial results 2023 biotechnology
Last updated: Feb 28, 2024